Business description: IXICO plc

IXICO plc is engaged in neuroscience imaging and biomarker analytics, using its artificial intelligence (AI)-driven platform to help advance drug development in neurological disorders. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.

Number of employees: 79

Sales by Activity: IXICO plc

Fiscal Period: September 2021 (GBP) 2022 (GBP) 2023 (GBP) 2024 (GBP) 2025 (GBP)

Medical Labs & Research

9.19M 8.64M 6.66M 5.77M 6.53M

Geographical breakdown of sales: IXICO plc

Fiscal Period: September 2021 (GBP) 2022 (GBP) 2023 (GBP) 2024 (GBP) 2025 (GBP)

United States of America

1.86M 2.71M 3.05M 2.36M 2.87M

United Kingdom

1.98M 2.06M 952K 1.33M 1.79M

Netherlands

1.25M 436K 862K 742K 623K

Denmark

- - - - 407K

Switzerland

3.25M 2.08M 816K 500K 398K

Ireland

482K 724K 689K 557K 304K

Other - Europe

370K 638K 293K 272K 136K

Rest of World

- - - - 6K

Executive Committee: IXICO plc

Manager TitleAgeSince
Chief Executive Officer 53 2024-08-18
Director of Finance/CFO 50 2019-08-20
Chief Tech/Sci/R&D Officer - 2025-05-31
Chief Tech/Sci/R&D Officer - 2020-12-31
Corporate Officer/Principal - 2026-02-04

Composition of the Board of Directors: IXICO plc

Director TitleAgeSince
Chairman 51 -
Director/Board Member 50 2019-08-20
Director/Board Member 60 2022-01-20
Director/Board Member 62 2023-10-04
Director/Board Member 53 2024-08-18

Shareholders: IXICO plc

NameStocks%Valuation
Canaccord Genuity Asset Management Ltd.
11.24 %
24,500,906 11.24 % 3 M p
Unicorn Asset Management Ltd.
9.969 %
21,737,555 9.969 % 3 M p
Gresham House Asset Management Ltd.
7.393 %
16,120,584 7.393 % 2 M p
BGF Investment Management Ltd.
5.91 %
12,887,000 5.91 % 2 M p
Octopus Investments Ltd.
4.541 %
9,902,257 4.541 % 1 M p

Company details: IXICO plc

Ixico Plc

Griffin Court

EC1A 9PN, London

+44 20 3763 7499

http://ixico.com
address IXICO plc(IXI)

Other Biotechnology & Medical Research

Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-33.46%-52.60% 25.27M
-1.40%+0.12%-14.73%-12.42% 43.68B
+3.56%-4.39%+264.94%+488.15% 30.65B
-1.24%-4.61%+12.23%-15.88% 30.4B
-0.67%-7.18%-0.98%+21.87% 29.31B
-0.66%-7.13%+7.59%+12.76% 24.2B
+2.63%+3.09%+56.42%+116.90% 13.3B
+4.00%-0.73% - - 13.03B
-1.65%-1.08%+7.92%+8.03% 13.21B
+0.93%-2.16%+103.12%+76.58% 12.12B
Average +0.66%-0.87%+44.78%+71.49% 20.99B
Weighted average by Cap. +0.46%-1.44%+51.34%+88.76%
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0865GBP
Average target price
0.2600GBP
Spread / Average Target
+200.58%

Annual profits - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!